Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952295 | 0.83 | EGFR (0.66) | NPC1EGFRERBB3MKNK1TNNI3K | |
| Hydrochloric Acid SCHEMBL2173883 | 0.82 | EGFR (0.64) | NPC1EGFRERBB3MKNK1TNNI3K | |
| SCHEMBL857502 | 0.81 | NPC1 (0.63) | NPC1EGFRERBB3MKNK1TNNI3K | |
| SCHEMBL2279563 | 0.81 | MEN1 (0.56) | NPC1EGFRERBB3MKNK1MEN1 | |
| SCHEMBL691533 | 0.81 | EGFR (0.57) | NPC1EGFRERBB3TNNI3K | |
| SCHEMBL2279629 | 0.81 | EGFR (0.59) | NPC1EGFRERBB3MKNK1TNNI3K | |
| SCHEMBL20093470 | 0.81 | NPC1 (0.51) | NPC1EGFRERBB3MKNK1TNNI3K | |
| SCHEMBL657571 | 0.81 | TP53 (0.62) | NPC1EGFRERBB3MKNK1TP53 | |
| Hydrochloric Acid SCHEMBL2176643 | 0.80 | NPC1 (0.61) | NPC1EGFRERBB3MKNK1TNNI3K | |
| SCHEMBL1243031 | 0.79 | EGFR (0.51) | NPC1EGFRERBB3MKNK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982036-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | NPC1 48/4885EGFR 1981/4885ERBB3 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.